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General: The solvents and chemicals used were of commercial grade. N-(2, 6-diisopropylphenyl)-4-bromo-naphthalene 1,8-dicarboximide (6), N-(2, 6-diisopropylphenyl)-9-bromo-perylene 3, 4-dicarboximide (7), N-(2, 6-diisopropylphenyl)-1,6,9,14-tetrakis(4-(1,1,3,3-tetramethylbutyl) phenoxy)-11-bromo-terrylene 3,4-dicarboximide (8) and N-(2, 6-diisopropylphenyl)-1,6-bis (4- (1,1,3,3-tetramethylbutyl)phenoxy)-13-bromo-quarterrylene 3, 4-dicarboximide (9) were synthesized as previously described [1] [2] [3] . Column chromatography was performed on silica gel (Geduran Si 60 , Merck). 1 H, 13 C, H, H COSY and NOE NMR were recorded on Bruker DPX 250, DRX 500 and Avance 700 NMR spectrometers. Infrared spectra were obtained on a Nicolet FT IR320. FD mass spectra were recorded with a VG-instruments ZAB 2-SE-FPD instrument.
MALDI-TOF mass spectra were recorded on a Bruker MALDI-TOF spectrometer. UV/Vis/NIR spectra were recorded in 1-cm quartz cuvette on a Perkin-Elmer Lambda 900 spectrophotometer.
Elemental analyses were performed by the Department of Chemistry and Pharmacy of the University of Mainz.
General procedure for Buchwald condition.
The bromo-RI (0.18 mmol), 4-aminobenzonitrile (0.36 mmol), tris-(dibenzylideneacetone)-dipalladium(0) (17 mg, 0.018 mmol), tris-tert-butylphosphine (18 mg, 0.09mmol), sodium-tert-butoxide (67 mg, 0.69 mmol) and dry toluene (10 mL) were stirred at 80°C under argon overnight. After cooling, the mixture was evaporated in vacuo and purified by a column chromatography on silica gel using dichloromethane as an eluent.
N-(2,6-diisopropylphenyl)-4-( (p-cyanophenyl)amino)naphthalene 1,8-dicarboximide (2)
Using 6, the general procedure afforded the title compound (81 mg, 95% 
N-(2, 6-diisopropylphenyl)-9-( (p-cyanophenyl)amino)perylene 3,4-dicarboximide (3a)
Using 7, the general procedure afforded the title compound (90 mg, 84% 
N-(2, 6-diisopropylphenyl)-9-( (p-octylphenyl)amino)perylene 3,4-dicarboximide (3b)
Using 7 and p-octylaniline instead of 4-aminobenzonitrile, the general procedure afforded the title compound (95 mg, 77% 
N-(2, 6-diisopropylphenyl)-1,6,9,14-tetrakis(4-(1,1,3,3-tetramethylbutyl)phenoxy)-11-( (pcyanophenyl)amino)terrylene 3,4-dicarboximide (4)
Using 8, the general procedure afforded the title compound (28 mg, 55% 
